

## Clinical Guideline

### Saturation targeting in the infant admitted to the Neonatal Unit

**Authors:** **Neonatal Saturation Targeting Working Group**  
 P. Cawley<sup>1</sup>, J. Talbot<sup>2</sup>, C. O'Mara<sup>3</sup>, E Musgrave<sup>4</sup>, J. Kapadia<sup>5</sup>

<sup>1</sup>*Paediatric Specialty Trainee Registrar, Norfolk & Norwich University Hospital*

<sup>2</sup>*Practice Development Sister, Watford General Hospital*

<sup>3</sup>*Lead Nurse/Innovation Lead, East of England Neonatal ODN*

<sup>4</sup>*Paediatric Specialty Trainee Registrar, Luton & Dunstable University Hospital*

<sup>5</sup>*Consultant Neonatologist, Luton & Dunstable University Hospital*

**For use in:** East of England Neonatal Units  
 Guidance specific to the care of inpatient neonatal patients  
 Guideline does not cover the provision for infants on home oxygen

**Used by:** All Neonatal / Paediatric Medical & Nursing staff

**Key Words:** Saturation Targeting, Oxygen Therapy, Neonate, Retinopathy of Prematurity (ROP), Chronic Lung Disease (CLD), Prematurity

**Guideline first produced:** January 2016

**Registration No:** NEO-ODN-2019-6

**Approved by:**

Neonatal Clinical Oversight Group	<b>12<sup>th</sup> December 2019</b>
Network Director	

## Contents

<b>TABLE OF SATURATION TARGETS AND LIMITS.....</b>	<b>3</b>
<b>ASSESSMENT &amp; MANAGEMENT OF THE DESATURATING NEONATE .....</b>	<b>4</b>
<b>SPECIAL CIRCUMSTANCES.....</b>	<b>6</b>
SATURATION TARGETING IN THE INFANT WITH A SPONTANEOUS PNEUMOTHORAX.....	6
SATURATION TARGETING IN THE PRETERM INFANT .....	6
<i>Chronic Lung Disease (CLD) &amp; Retinopathy of Prematurity (ROP) .....</i>	<i>6</i>
<i>Saturation Targeting at 37 Weeks Corrected Gestation and Prior to Discharge .....</i>	<i>6</i>
PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) .....	7
SUSPECTED CONGENITAL HEART DISEASE (CHD) .....	8
<b>SATURATION TARGETING IN THE DELIVERY SUITE.....</b>	<b>8</b>
TERM & PRETERM INFANTS .....	8
<b>BACKGROUND &amp; THEORY OF PRACTICE .....</b>	<b>9</b>
OXYGEN TARGETING IN THE NEONATAL PERIOD .....	10
BENEFITS OF SATURATION MONITORING .....	10
LIMITATIONS AND PITFALLS OF SATURATION MONITORING.....	11
AEROBIC RESPIRATION & OXYGEN DELIVERY .....	11
HAEMOGLOBIN OXYGEN SATURATIONS.....	12
FUNCTIONAL VERSUS FRACTIONAL PULSE OXIMETRY .....	12
THE RELATIONSHIP BETWEEN PAO <sub>2</sub> AND SAO <sub>2</sub> .....	12
PLACEMENT OF PULSE OXIMETER PROBES .....	13
<b>TABLE OF EVIDENCE .....</b>	<b>15</b>
<b>REFERENCES AND FURTHER READING .....</b>	<b>17</b>
<b>APPENDICES.....</b>	<b>18</b>
APPENDIX A: <i>ACKNOWLEDGEMENTS.....</i>	<i>18</i>
APPENDIX B: <i>THE PRESCRIPTION OF OXYGEN THERAPY &amp; OXYGEN PRESCRIPTION STICKERS.....</i>	<i>18</i>
APPENDIX C: AUDIT STANDARDS & AUDIT PROFORMA .....	19
<b>COPYRIGHT STATEMENT &amp; DISCLAIMER .....</b>	<b>21</b>
<b>EXCEPTIONAL CIRCUMSTANCES FORM .....</b>	<b>21</b>

## Table of Saturation Targets and Limits

Gestation	Air/Oxygen	Target	Alarm Limits
Preterm <37 weeks Or Birth Weight <1.5kg	Oxygen	91 - 95%	90 - <b>96%*</b>
	Air	91 - 95%	90 – 100%
Term Infant ≥37 weeks	Oxygen	≥95%	94 - 99%
	Air	≥95%	94 - 100%
Preterm infant with corrected gestation ≥37 weeks	Oxygen	≥93%	92 - 99%
	Air	≥93%	92 – 100%

All infants <34 weeks gestation, and all infants on supplementary oxygen or any invasive or non-invasive ventilatory support must be commenced on continuous pulse oximetry

<b>Special Circumstances</b>			
Circumstance	Air/Oxygen	Target	Alarm Limits
Risk of PPHN**/ Established PPHN	Air/Oxygen	>95%	95 - 100%
Suspected or Confirmed Cyanotic Heart Disease	See CATS Clinical Guideline: <b>“Duct Dependant Congenital Heart Disease”</b>		
	<i>Avoid Hyperoxia – Particularly in duct-dependent lesions*** Liaise with Specialist Cardiac Centre for Advice</i>		

**\*Preterm infants with saturations >95% in oxygen are at significant risk of hyperoxia**  
PaO<sub>2</sub> will be significantly elevated; act with the same urgency as a significant desaturation

**\*\*Risk Factors for PPHN in Term or Near Term Infant:**

Meconium Aspiration, GBS sepsis or congenital pneumonia, Severe perinatal Hypoxic Ischaemic Encephalopathy (HIE), Structural Lung Disease such as *Pulmonary hypoplasia, congenital diaphragmatic hernia or congenital pulmonary malformation*, Maternal Factors such as use of *Aspirin / Non-Steroidal Anti-Inflammatory Drug (NSAID) / Selective Serotonin Receptor Inhibitor (SSRI) / Smoking / Ill-health through asthma, diabetes mellitus, raised BMI*

**\*\*\*Limited evidence base for oxygen targeting in Cyanotic Heart Disease**

- Saturations >85% are unlikely to be achievable without significant hyperoxia (PaO<sub>2</sub>), due to the physiological effect of shunting/mixing
- Hyperoxia must be avoided due to risk of unintended ductal closure
- Saturations may be less than 75% in certain cyanotic cardiac lesions – liaison with cardiac specialists is imperative to guide optimal targeting

## Assessment & Management of the Desaturating Neonate

The neonate, particularly at preterm, will commonly display variation in oxygen saturations. Fleeting and self-correcting desaturations are unlikely to be of clinical significance and efforts must be made to **avoid the hyperoxaemic swings** that are created by the addition of unnecessarily high fractions of inspired oxygen ( $FiO_2$ ).

If a significant desaturation (i.e. prolonged or severe) does occur, manage the infant according to the ABC routine. Ensure adequate respiratory effort and air entry **prior** to increasing the  $FiO_2$ . Many desaturations will correct without intervention, and failing that, with simple stimulation or manual/ventilator breaths.

*An increase in  $FiO_2$  alone is likely to be ineffective, and potentially detrimental, in an infant demonstrating desaturation due to apnoea, reflux or any cause of hypoventilation.*

*Never walk away from an infant who is requiring an acute increase in  $FiO_2$ : **they are at risk of both rebound hyperoxaemia and further deterioration.***

The algorithm below (next page) may be used as an example of the appropriate management of the desaturating neonate. Several steps may be taken prior to increasing the  $FiO_2$ .


The following should be clearly recorded on an infant's observation chart:

- Significant desaturations (not artefactual *and* prolonged or requiring intervention)
- Bradycardia
- Apnoeic spells (sustained absence of respiratory effort combined with significant desaturation or bradycardia, **or** absence of respiratory effort for >20 seconds without other clinical manifestation)

*- Ensure that the lowest saturation, lowest heart rate and intervention required are cited*

A preterm infant with an increase in frequency or severity of desaturations or bradycardias should receive prompt medical review. Symptomatic apnoeic episodes are of particular concern and low threshold should be held for escalation of respiratory support and appropriate septic management.

Desaturation, bradycardia and apnoeic episodes in the term infant are almost always pathological and warrant medical investigation and intervention.



## Special Circumstances

No guideline can cover all potential clinical scenarios faced on the neonatal unit. The table of recommended saturation targets should cover most clinical scenarios. Individual saturation ranges may be prescribed as and when necessary – though the reasons for doing so should be clearly documented in the infant’s medical notes.

### Saturation Targeting in the Infant with a Spontaneous Pneumothorax

Detailed management of neonatal pneumothorax is beyond the scope of this guideline. These infants are at risk of deterioration; they require close monitoring, continuous pulse oximetry and management according to the ABC approach.

Supplemental oxygen should be provided to maintain the infant’s oxygen saturations within the recommended target range for their gestation. Evidence does not support the routine use of high FiO<sub>2</sub> to provide the ‘nitrogen washout’ technique’. In fact, it exposes the infant to the risk of hyperoxia. In addition, the unnecessary administration of a high FiO<sub>2</sub> can mask deterioration in the neonate’s condition, as any true increase in **oxygen requirement** is concealed until it surpasses the FiO<sub>2</sub> that is being administered.

### Saturation Targeting in the Preterm Infant

#### Chronic Lung Disease (CLD) & Retinopathy of Prematurity (ROP)

Very premature and very low birth weight infants are at particular risk of chronic lung disease and retinopathy of prematurity. Although targeting saturations at a range 85-89% does reduce the incidence of ROP and, to some extent chronic lung disease, it leads to an unacceptable increase in mortality. As such, a saturation target range of 91-95% should be followed. Of note, although incidence of ROP increases when targeting saturations of 91 to 95%, when compared with 85 to 89%, no significant difference in visual impairment (including nystagmus, strabismus, the use of corrective lenses and unilateral/bilateral blindness) has been observed in the NeOProm studies reporting follow-up to 18-22 months.

The saturations target range of 91-95% should be maintained in extremely and very preterm infants, even after 32 weeks corrected gestation and **regardless of the presence or absence of CLD, ROP or confirmed complete vascularisation of the retina**. Targeting saturations >95% in this group substantially increases the duration of their inpatient oxygen requirement and significantly increases their risk of requiring home oxygen therapy without any significant difference in growth profile, neurodevelopmental status and mortality rate at 12 months.

#### Saturation Targeting at 37 Weeks Corrected Gestation and Prior to Discharge

In the very premature and extremely premature infant with corrected gestation at or beyond 37 weeks (or prior to this if being considered for discharge from the neonatal unit) saturations ≥93% should be targeted in order to aid transition to community care and paediatric standards. Infants discharged home are susceptible to pulmonary hypertension, secondary to chronic hypoxia, if exposed to saturations <93% over a prolonged period.

The specific provisions and workup of the infant likely to require long-term home oxygen therapy is beyond the scope of this guideline. Further reference to the latest national guideline by the British Thorax Society (BTS), “**BTS Guidelines for Home Oxygen in Children**”, is recommended.

### **Persistent Pulmonary Hypertension of the Newborn (PPHN)**

Infants suffering from Persistent Pulmonary Hypertension of the Newborn (PPHN) are extremely unstable and critically unwell. They require senior management and are highly likely to require tertiary neonatal care. The management of PPHN is complex, multi-factorial and beyond the scope of this guideline, other than comments relevant to oxygen saturation targeting.

The infant at risk of PPHN (see box on page 3 (Delaney & Cornfield, 2012)) should have oxygen saturations maintained >95%. The infant with established PPHN will benefit from the vasodilating properties of liberal oxygen therapy, and as a result their oxygen saturations should be targeted as high as is physiologically possible.

Comparison of pre and post-ductal saturations will be highly informative. Measurement of the PaO<sub>2</sub> will also allow for calculation of the **Oxygen Index (OI)** (Noting that differences in pre and post-ductal PaO<sub>2</sub> may occur; the OI is classically, though not necessarily universally, calculated using the post-ductal PaO<sub>2</sub>). The OI will help inform decisions relating to both nitric oxide and Extra-Corporeal Membrane Oxygenation (ECMO) therapy.

In PPHN, a significant difference in pre and post ductal PaO<sub>2</sub> (>2.5 kPa) or O<sub>2</sub> saturations (5-10%) may occur.

$$\text{Oxygenation Index (OI)} = [\text{MAP} \times \text{FiO}_2] / [\text{PaO}_2 \times 7.5]$$

Given:

**MAP:** Mean Airway Pressure (**cmH<sub>2</sub>O**)

**FiO<sub>2</sub>:** ‘Fraction’ of Inspired Oxygen as percentage (%)

**PaO<sub>2</sub>:** Partial Pressure of Oxygen in Arterial Blood (**kPa**)

## Suspected Congenital Heart Disease (CHD)

Infants with congenital and/or cyanotic heart disease require specific individualised saturation targets according to the precise anatomical defect, whether the defect is duct dependant and whether any palliative or corrective procedures have been undertaken. Liaison with cardiac specialist centres is recommended.

In the emergent presentation of an infant with a previously unsuspected congenital heart lesion, please refer to the Children's Acute Transport Service (CATS) Clinical Guideline "**Duct Dependant Congenital Heart Disease**".

This is available on the CATS website – follow the links for '**IN A HURRY**' and '**Clinical Guidelines**', and select guideline '**Congenital Heart Disease**'.

Direct Hyperlink: <http://site.cats.nhs.uk/in-a-hurry/cats-clinical-guidelines/>

Prompt liaison and referral to a cardiac specialist centre and the CATS team should then take place.

### Saturation targeting in the delivery suite

This guideline advocates the use of UK Resuscitation Council's NLS recommendations (4<sup>th</sup> Ed.2016) for the resuscitation of term and preterm infants at delivery

<https://www.resus.org.uk/resuscitation-guidelines/resuscitation-and-support-of-transition-of-babies-at-birth/>

## Background & Theory of Practice

### Oxygen Targeting in the Neonatal Period

Pulse oximetry may be used in the neonatal period to help mitigate and negotiate the risks posed by both relative hypoxaemia and hyperoxaemia.

#### *Term infants*

Limited evidence exists regarding pulse oximeter saturation targeting in term Infants with no randomised control trials comparing saturation ranges. Whilst term babies >1.5kg are not at risk of ROP, hyperoxaemia may still compromise cerebral perfusion and exacerbate oxidative stress in the presence of a hypoxic-ischaemic insult. Guidance relating to pulse oximeter saturation targeting in term babies must therefore be based on observed normal ranges, aimed at avoiding the precipitation of PPHN and minimising the risk of missing a potential congenital cardiac lesion. In this light, pulse oximeter saturation targeting, and decisions to start oxygen therapy must be informed by clinical assessment of individual infants.

Observational studies reveal that healthy term infants' pulse oximeter saturations range from 89-100% (Median 98.3%) in the first 24 hours of age, and 92 to 100% (Median 97.6%) in the first week of age. In the majority of infants, acclimatisation to pulse oximeter saturations >95% (pre & post-ductal) occurs rapidly, taking on average 12 to 14 minutes post-delivery. (O'Brien et al, 2000; Poets et al, 1996; Toth et al, 2002)

#### *Preterm infants*

A significant body of evidence now exists regarding the study of pulse oximeter saturation targeting in preterm and extreme preterm infants is now available. Hyperoxaemia in the preterm infant is associated with the development of both Chronic Lung Disease (CLD) & Retinopathy of Prematurity (ROP). Hypoxaemia is associated with increased mortality and the development of Necrotising Enterocolitis (NEC).

The **BOOST** and **STOP-ROP** trials provide evidence that targeting saturations >95% is deleterious to preterm infant health.

The original **BOOST trial** (Benefits of Oxygen Saturation Targeting) was a multi-centre double-blinded RCT involving a total of 358 participating infants born at <30 weeks gestation (mean gestation was 26.6). The trial compared target saturations of 91 to 94% vs 95 to 98%; starting at corrected gestations >32 weeks and continued until oxygen therapy was no longer required. Between the two groups, no significant difference in growth profile, neurodisability at 12 months, grade of ROP, nor progression to surgical treatment of ROP, was observed. Despite observed absence of benefit, infants in the higher saturations group demonstrated a greater incidence of CLD; they required double the duration of inpatient oxygen therapy (40 vs 18 days), had a significantly increased frequency of home-oxygen therapy requirement (17 vs 30%, RR 1.78, CI 1.20 to 2.64, P=0.004) and a statistically non-significant increase in deaths relating to pulmonary causes.

The **STOP-ROP** trial (Supplemental Therapeutic Oxygen for Pre-threshold Retinopathy of Prematurity) recruited 649 infants born at <31 weeks gestation or <1.5kg birth weight, with pre-threshold ROP. Randomisation to two target saturation groups (89-94% vs 96-99%) took place at 6 –

10 weeks of age and continued until either regression of ROP, or progression of ROP to threshold had occurred. The authors reported an increase in exacerbations of CLD and pneumonia, length of stay and diuretic therapy in the higher saturations group. Effect on ROP progression was minimal and no difference in growth and developmental milestones was observed.

The **NeOProm** collaboration provides evidence that targeting saturations <91% in extremely preterm infants contributes to an increase in mortality and the development of NEC.

The **NeOProm** collaboration (formed of 5 prospectively planned RCTs with similar methodology: **COT**, **BOOSTII** [UK, NZ, AU] & **SUPPORT**) compared death, neurodisability and rates of ROP, plus multiple secondary outcomes, in extreme preterm infants in two randomised groups: 91-95% vs 85-89%. Relative risk of death was increased in the lower saturations groups (RR 1.18-1.41) and rates of NEC increased in the lower saturations group by 25% (RR 1.25). A substantial 26% reduction in severe ROP was observed in the lower saturations group (RR 0.74), though this effect is somewhat negated, given that no significant increase in bilateral blindness or visual impairment has been observed in the 3 trials published so far with follow-up to 18 to 24 months (BOOST II NZ, COT & SUPPORT). The occurrence of physiologic BPD tended towards the higher saturation group, but this effect was small (37.6% vs 39.7%, RR 0.86, CI 0.77-0.96). No substantial differences were observed between the two groups in the occurrence of PDA & 'brain injury'.

## Benefits & Limitations / Pitfalls of Saturation Monitoring

The implementation of pulse oximetry has considerably reduced the need for repeat arterial blood sampling, is non-invasive, enables continuous monitoring, and is a reflection of a greater proportion of an infant's total oxygen content than PaO<sub>2</sub> interpreted in isolation.

On the other hand, pulse oximetry is liable to inaccuracy due to movement artefact, cool / poorly perfused peripheries, ambient light (causing interference with the probe's spectrophotometer), and in infants with high total carboxyhaemoglobin levels (CarboxyHb has a similar absorbance to oxyhaemoglobin and may falsely elevate pulse oximeter readings).

It is important to consider that pulse oximeter saturations only represent a **percentage** of the haemoglobin-bound oxygen content of blood. Pulse oximeter saturations **do not reflect an absolute value** for the haemoglobin-bound oxygen content of an infant's blood.

***i.e.** an **anaemic** infant's total oxygen content of blood, or total oxygen-carrying capacity, will be much less than a **polycythaemic** infant, even if their pulse oximeter saturations are identical*

An infant's *total oxygen content* is also dependent on their PaO<sub>2</sub> and the absolute value of circulating haemoglobin

There are reported cases of significant burns occurring from pulse oximeter probe sites, particularly in premature infants with thin skin, and when probes are not placed according to manufacturer instructions. The risk of burns may be mitigated, but not eliminated, by regular skin integrity checks

and probe site rotation.

## Aerobic Respiration & Oxygen Delivery

Oxygen is a vital element for **aerobic respiration** to occur. Through aerobic respiration, each cell in the human body is able to produce 'chemical' energy, known as **ATP (Adenosine triphosphate)**. ATP is required to fuel almost every metabolic process in the body. At the final stage of aerobic respiration, oxygen acts as the final electron acceptor in a process known as the **Electron Transport Chain**, which takes place in the mitochondria. Without oxygen aerobic respiration cannot take place and consequently cells have to switch to inefficient **anaerobic respiration**; this produces far less energy and also leads to the accumulation of **lactic acid**.

It is therefore vital that the body maintains **oxygen delivery** to all tissues via the blood supply. Oxygen delivery is the product of the blood flow through the body each minute (**Cardiac Output**) and the **oxygen content** of that blood.

The **oxygen content** of blood is the sum of both the amount of oxygen bound to **haemoglobin (Hb)** in the blood, plus the amount of unbound oxygen dissolved within the blood (the **partial pressure of oxygen**).

Oxygen is delivered to the body's tissues via arterial blood. Following consumption of oxygen within the capillary bed and tissues, deoxygenated blood returns to the heart via the veins, where it is subsequently pumped to the lungs to be re-oxygenated. This natural process may be disturbed in diseased states or following therapeutic interventions – such as the interruption of gas diffusion in pneumonia or the administration of oxygen at supra- physiological values (>21%). Therefore, the oxygen content of blood may fall out of normal physiological parameters, such as in the following definitions:

<b>Hypoxaemia:</b>	Low total oxygen content within the blood
<b>Hypoxia:</b>	The resultant <i>oxygen deficiency</i> within the body's tissues & organ systems
<b>Hyperoxaemia:</b>	High total oxygen content within the blood – specifically expressed as a high <b>PaO<sub>2</sub></b> (Partial Pressure of Oxygen in <b>arterial</b> blood)
<b>Hyperoxia:</b>	The resultant oxygen excess within the body's tissues and organ systems

## Haemoglobin Oxygen Saturations

Each haemoglobin molecule is able to bind to a maximum of four oxygen molecules. It is therefore possible to express the oxygen saturation of the blood as a percentage, based on how many oxygen molecules have associated with each haemoglobin molecule.

**Pulse oximetry** provides a non-invasive estimate of the **oxygen saturation of haemoglobin in arterial** blood. The pulse oximeter probe uses **spectrophotometry** (the relative absorbance of red and infrared light of each haemoglobin molecule) to distinguish between haemoglobin with a high number of associated oxygen molecules (**oxyhaemoglobin**) and haemoglobin with a low number of associated oxygen molecules (**deoxyhaemoglobin**). The probe is able to differentiate arterial blood due to the pulsatile nature of the arteries. The pulse oximeter will then provide a percentage

saturation of oxygen, which has been averaged over a predefined period of time (usually around 15

seconds – though pulse oximeters at deliveries should be set to a much shorter averaging time of around 2 seconds).


### Functional Versus Fractional Pulse Oximetry

Traditional pulse oximeters measured ‘fractional’ oxygen saturations, i.e. the percentage of oxygenated haemoglobin when compared with total haemoglobin content (including oxyhaemoglobin, deoxyhaemoglobin, carboxyhaemoglobin & methaemoglobin). Newer pulse oximeters, and those used in the most recent clinical trials, report ‘functional’ oxygen saturations, i.e. the percentage oxygenation of haemoglobin which may **functionally** transport oxygen within the bloodstream (Oxyhaemoglobin vs deoxyhaemoglobin).

Functional pulse oximeters report oxygen saturations approximately 1.5% higher than fractional pulse oximeters. **The target oxygen saturation ranges recommended within this guideline are in reference to functional pulse oximeters.**

### The Relationship between PaO<sub>2</sub> and SaO<sub>2</sub>

PaO<sub>2</sub> is the measure of oxygen dissolved within the arterial blood stream (Partial Pressure of oxygen). The percentage of oxygenated haemoglobin within arterial blood (SaO<sub>2</sub>) is proportional to PaO<sub>2</sub> through a dynamic relationship that changes according to the **sigmoid shaped oxygen-haemoglobin dissociation curve**. A schematic of this curve is displayed below.




Schematic diagram to demonstrate, and compare, sigmoid dissociation of oxygen from HbF & HbA in differing partial pressures of oxygen.


## Placement of Pulse Oximeter Probes

The pulse oximeter probe may be placed on any of the infant's 4 limbs. According to anatomical site, a given pulse oximeter reading may be interpreted as pre- or post-ductal. 'Pre-ductal' refers to all arterial branches of the aorta *prior* to the connection of the ductus arteriosus, from the pulmonary arteries to the aorta. Likewise, 'post-ductal' refers to all arterial branches of the aorta *after* the connection of the ductus arteriosus from the pulmonary arteries to the aorta. The following 3 figures provide a series of anatomical schematics to demonstrate this. Physiological studies demonstrate that, in the majority of cases, the left arm is pre-ductal equivalent, though this should not be assumed in infants with complex congenital cardiac lesions or in infants with established PPHN. (egger et al, 2010)

A fabric wrap should be used around the pulse oximeter probe site in order to minimise ambient light interference.



Schematic to demonstrate which limbs are attributable to pre- and post-ductal circulation. In the healthy term infant, the left hand may be considered "pre-ductal equivalent".



*Schematic diagram to demonstrate the pre- and post-ductal circulations according to the body's major arteries. In the healthy term infant, the left hand may be considered "pre-ductal equivalent", but this may not be the case in established PPHN, transitional circulation & in certain congenital cardiac lesions.*

## Table of Evidence

Recommendation	Rationale	Grade of Recommendation* & Reference	
<b>Target saturation range 91-95% preferable to 85-89% in the extreme preterm neonate</b>	Reduced mortality and rate of NEC without increase in risk of neurodisability	A	Saugstad & Aune, 2014
<b>Saturations &gt;95% should be avoided in the very low birth weight &amp; extremely premature neonate</b>	Increased rate of ROP & CLD, without benefit in mortality or other co-morbidities	A	Saugstad & Aune, 2011
<b>Saturation range of 91-95% applicable to corrected gestational ages up to 37 completed weeks</b>	Targeting saturations >95% in extreme preterm neonates at corrected gestational ages >32 weeks bears no advantage in growth profile, neurodisability, or grade of ROP. Targeting saturations >95% is associated with a greater incidence of CLD, length of stay, duration of inpatient oxygen therapy and progression onto home-oxygen therapy requirement	B	BOOST STOP-ROP
<b>Alarm limits should be prefixed to encourage tight control within the targeted range (i.e. to alarm at 1% above and 1% below target range)</b>	In comparing major trials, better control was achieved in the RCT with specified alarm limits (COT) versus those that did not specify limits (BOOST II). Even in specifying limits within 2% (COT), or suggesting limits within 3% (SUPPORT), of target range - median oxygen saturations were out of range for a significant portion of time. Compliance with target limits is poor in all trials to date; no studies provide a definitive solution to alarm fatigue, nor definitive answer with respect to alarm limit to target tolerance.	-	COT BOOST II SUPPORT

<p><b>Target saturations <math>\geq 93\%</math> in preterm infants with corrected gestation <math>\geq 37</math> weeks, or prior to this if planning for discharge</b></p>	<p>Infants with CLD are at increased risk of Apparent Life Threatening Events (ALTE) with saturations below 90% - at saturations <math>&gt;93\%</math> they are not. Saturations less than 92% long term, may be associated with suboptimal growth in infants with CLD. Saturations above 94–95% appear to reduce pulmonary hypertension, while levels below 88–90% may cause pulmonary hypertension. (Not applicable to congenital cardiac lesions, nor idiopathic pulmonary hypertension)</p>	<p>C</p>	<p>British Thoracic Society, 2009</p>
<p><b>Target saturations <math>\geq 95\%</math> in term infants</b></p>	<p>Saturations <math>&gt;95\%</math> reached on average 12 to 14 minutes post- delivery in healthy term infants. Median average saturations of 98.3% in the 1<sup>st</sup> 24 hours in healthy term infants. No trials directly compare saturation target ranges in term infants.</p>	<p>D</p>	<p>Toth et al. 2002 O'Brien et al. 2000</p>
<p><b>In an infant with pneumothorax, supplemental oxygen should be provided to maintain oxygen saturations within the recommended target range for their gestation</b></p>	<p>Unnecessary administration of oxygen beyond that required to maintain an infant's saturations within target range for gestation does not speed up pneumothorax resolution time but may expose the infant to the risks of hyperoxia as well as conceal or mask a true rise in the infants required <math>FiO_2</math></p>	<p>C</p>	<p>Shaheen et al. 2014</p>

\*Guyatt et al, 2008.

## References and Further Reading

**BOOST:** Askie L.M., Henderson-Smart D.J., Irwig L., Simpson J.M. Oxygen-Saturation Targets and Outcomes in Extremely Preterm Infants. *N Engl J Med* 2003;349:959-67.

**BOOST II:** The BOOST II United Kingdom, Australia, and New Zealand Collaborative Groups. Oxygen Saturation and Outcomes in Preterm Infants. *N Engl J Med* 2013;368:2094-104.

BOOST II: The BOOST II Australia and United Kingdom Collaborative Groups. Outcomes of two trials of oxygen saturation targets in preterm infants. *N Engl Med* 2016;374:397-60

British Thoracic Society; Home Oxygen Guideline Development Group. Guidelines for home oxygen in children. *Thorax*; 2009. Vol 64 Supplement II

**COT:** Schmidt B., Whyte R.K., Asztalos E.V., Moddemann D., Poets C., Rabi Y., Solimano A., Roberts R.S. For the Canadian Oxygen Trial (COT) Group. Effects of Targeting Higher vs Lower Arterial Oxygen Saturations on Death or Disability in Extremely Preterm Infants A Randomized Clinical Trial. *JAMA* 2013;309 (20): 2111- 2120

Delaney C., Cornfield D.N. Risk factors for persistent pulmonary hypertension of the newborn. *Pulmonary Circulation*; 2012: 2(1):15 - 20

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–926

Shaireen H., Rabi Y., Metcalfe A., Kamaluddeen M., Amin H., Akierman A., Lodha A. Impact of oxygen concentration on time to resolution of spontaneous pneumothorax in term infants: a population based cohort study. *BMC Pediatrics* 2014;14:208

**NeOProm:** Askie L.M., Brocklehurst P., Darlow B., Finer N., Schmidt B., Tarnow-Mordi W., for the NeOProm Collaborative Group. NeOProm: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol. *BMC Pediatrics* 2011;11:6

Newborn Life Support - Resuscitation at Birth (3rd edition). March 2011. UK Resuscitation Council.

O'Brien L.M., Stebbens L.M., Poets C.F., Heycock E.G., Southall D.P. Oxygen saturation during the first 24 hours of life. *Arch Dis Child Fetal Neonatal Ed.* 2000;83:F35-F38

Poets C.F. et al. Arterial oxygen saturation in healthy term neonates. *Eur J Pediatr* 1996;155:219-223

Rüegger C., Bucher H.U., Mieth R.A. Pulse oximetry in the newborn: Is the left hand pre- or post-ductal? *BMC Pediatrics* 2010;10:35

Saugstad O.D., Aune D. In Search of the Optimal Oxygen Saturation for Extremely Low Birth Weight Infants: A Systematic Review and Meta-Analysis. *Neonatology* 2011;100:1–8

Saugstad O.D., Aune D. Optimal Oxygenation of Extremely Low Birth Weight Infants: A Meta-Analysis and Systematic Review of the Oxygen Saturation Target Studies. *Neonatology* 2014;105:55–63

**STOP-ROP:** The STOP-ROP Multicenter Study Group\* Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), A Randomized, Controlled Trial. I: Primary Outcomes. *Pediatrics* 2000;105(2):295- 310

**SUPPORT :** Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network Target Ranges of Oxygen Saturation in Extremely Preterm Infants. *N Engl J Med* 2010;362:1959-69.

Toth B., Becker A., Seelbach-Göbel B. Oxygen saturation in healthy newborn infants immediately after birth

measured by pulse oximetry. Arch Gynecol Obstet. 2002 Apr;266(2):105-7

## Appendices

### Appendix A: Acknowledgements

The neonatal saturation targeting working group would like to acknowledge Dr David Booth, consultant neonatologist at Norfolk & Norwich University Hospital, and Dr Ambika Rajesh, paediatric specialty trainee registrar at Norfolk & Norwich University Hospital, for their involvement in the pre-guideline region wide survey, which greatly informed the need for a region wide neonatal saturation guideline.

**Appendix B: The Prescription of Oxygen Therapy & Oxygen Prescription Stickers** The provision of oxygen to an infant should be regarded as the administration of a medication. As such, trusts should ensure an adequate system is in place to streamline oxygen prescription on medication cards/drug charts.

As a standard of good practice, the oxygen prescription should then be acknowledged and validated by administering nursing staff by signing against the prescription at twice daily intervals (For example, at each shift change).

An Oxygen prescription sticker template may be requested from the EoE neonatal network (Separate file). An example of an appropriate oxygen prescription template is given below:

<b>Oxygen Prescription: Titrate <math>FiO_2</math> to selected target range</b>	
Preterm (<37 weeks or <1.5kg):.....	91-95% <input type="checkbox"/>
Term ( $\geq 37$ weeks) .....	$\geq 95\%$ <input type="checkbox"/>
Preterm, corrected gestation $\geq 37$ weeks.....	$\geq 93\%$ <input type="checkbox"/>
Risk of /established PPHN .....	$>95\%$ <input type="checkbox"/>
Other:.....	____% to ____% <input type="checkbox"/>
<b>Signed:</b>	<b>Date:</b>

## Appendix C: Audit Standards & Audit Proforma

The first audit of practice should take place in each neonatal unit 6 months following the implementation of this guideline. Following this, audit of practice should take place annually.

A template audit proforma is provided on the next page.

Audit should assess:

- a) Compliance with saturation targets (Source: observation charts)
- b) Compliance with set limits (Real time assessment of set alarm limits on the unit)
- c) The following additional **audit standards**:

### Audit Standards:

- **100%** of infants receiving oxygen should have oxygen therapy prescribed on an appropriate drug chart, ***with oxygen target range specified***
- **100%** of infants receiving oxygen therapy should have continuous pulse oximetry monitoring, unless specifically documented by the medical team that this is not required (e.g. Stable near-discharge neonate who has been fully prepared and investigated for home oxygen)
- **100%** of infants receiving continuous pulse oximetry monitoring should have correct saturation alarm limits set according to gestation, age and clinical condition
- If individualised saturation range is prescribed, deviating from recommendations in the guideline table, then the reason for this should be documented in the medical notes in **100%** of cases

### Spot Check Audit: Saturation targeting for the Infant admitted to the Neonatal Unit

Date:

	1	2	3	4	5	6	7	8	9	10
Gestation										
Age < 24 hours Y/N										
Risk of/Established PPHN Y/N										
Confirmed Cyanotic Heart Disease Y/N										
O <sub>2</sub> being administered?										
O <sub>2</sub> Prescribed? Y/N										
O <sub>2</sub> Prescription Complaint with Guidance? Y/N										
On continuous pulse oximetry? Y/N										
Alarm Limits	/	/	/	/	/	/	/	/	/	/
Limits Compliant with Guidance? Y/N										

*Shaded cells are regional audit standards*

## Copyright Statement & Disclaimer

All Rights Reserved. The East of England Neonatal ODN withholds all rights to the maximum extent allowable under law. Any unauthorised broadcasting, public performance, copying or re-recording will constitute infringement of copyright. Any reproduction must be authorised and consulted with by the holding organisation (East of England Neonatal ODN).

The organisation is open to share the document for supporting or reference purposes but appropriate authorisation and discussion must take place to ensure any clinical risk is mitigated. The document must not incur alteration that may pose patients at potential risk. The East of England Neonatal ODN accepts no legal responsibility against any unlawful reproduction. The document only applies to the East of England region with due process followed in agreeing the content.

## Exceptional Circumstances Form

Form to be completed in the **exceptional** circumstances that the Trust is not able to follow ODN approved guidelines.

Details of person completing the form:	
Title:	Organisation:
First name:	Email contact address:
Surname:	Telephone contact number:
Title of document to be excepted from:	
Rationale why Trust is unable to adhere to the document:	
Signature of speciality Clinical Lead:	Signature of Trust Nursing / Medical Director:
Date:	Date:
Hard Copy Received by ODN (date and sign):	Date acknowledgement receipt sent out:

Please email form to: [mandybaker6@nhs.net](mailto:mandybaker6@nhs.net) requesting receipt.

Send hard signed copy to: Mandy Baker  
EOE ODN Executive Administrator  
Box 93, Cambridge University  
Hospital Hills Road

Cambridge CB2 0QQ